• Record: found
  • Abstract: found
  • Article: not found

Consistent safety and infectivity in sporozoite challenge model of Plasmodium vivax in malaria-naive human volunteers.

The American Journal of Tropical Medicine and Hygiene

Young Adult, physiology, immunology, Sporozoites, Random Allocation, therapeutic use, Primaquine, Plasmodium vivax, Parasitemia, Middle Aged, Male, transmission, parasitology, Malaria, Vivax, Humans, Fever, Female, Duffy Blood-Group System, Chloroquine, Antimalarials, Animals, Adult

Read this article at

      There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


      A safe and reproducible Plasmodium vivax infectious challenge method is required to evaluate the efficacy of malaria vaccine candidates. Seventeen healthy Duffy (+) and five Duffy (-) subjects were randomly allocated into three (A-C) groups and were exposed to the bites of 2-4 Anopheles albimanus mosquitoes infected with Plasmodium vivax derived from three donors. Duffy (-) subjects were included as controls for each group. Clinical manifestations of malaria and parasitemia were monitored beginning 7 days post-challenge. All Duffy (+) volunteers developed patent malaria infection within 16 days after challenge. Prepatent period determined by thick smear, was longer for Group A (median 14.5 d) than for Groups B and C (median 10 d/each). Infected volunteers recovered rapidly after treatment with no serious adverse events. The bite of as low as two P. vivax-infected mosquitoes provides safe and reliable infections in malaria-naive volunteers, suitable for assessing antimalarial and vaccine efficacy trials.

      Related collections

      Author and article information



      Malaria vaccine development collection topic 4) Major challenges for Plasmodium vivax vaccine development - challange models:


      The development of a safe and reproducible P. vivax sporozoite challenge model in malaria-naïve humans can greatly accelerate clinical development of P. vivax vaccines. Herrera et al. have demonstrated the robustness and reproducibility of the P. vivax sporozoite challenge model, which should allow evaluation of efficacy of both pre-erythrocytic and blood stage P. vivax vaccines. The use of sporozoite, as well as blood stage challenge models can greatly help validate and down select P. vivax vaccine candidates for further clinical testing in more time consuming and expensive field trials against natural challenge in endemic areas.



      2018-10-04 22:04 UTC

      Comment on this article